Exabis Library
Welcome to the e-CCO Library!
DOP71: Effects of ustekinumab induction therapy on endoscopic and histological healing in the UNIFI Phase 3 study in ulcerative colitis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP71: Fungal and bacterial gut microbiota in paediatric onset Inflammatory Bowel Disease introduced to infliximab
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP71: Low occurrence of colectomy with long-term (up to 4 years) golimumab treatment in patients with moderate-to-severe active Ulcerative Colitis: Data from the PURSUIT maintenance and long-term extension studies
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP71: TREM1, OSM and a co-expressed transcriptional module are core components of the molecular resistome to anti-cytokine therapy in Ulcerative Colitis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP72 Safety, tolerability and efficacy of anti-TL1A antibody PF-06480605 in treatment of ulcerative colitis: The open-label, multicentre, Phase 2a TUSCANY study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP72: HLA-DQA1*05 associates with immunogenicity and loss of response to anti-TNF therapy in the IBD population: A meta-analysis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP72: Increased risk of advanced neoplasia in inflammatory bowel disease patients with recurrent low-grade dysplasia
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP72: Perianal Crohn’s Disease in the biologic era: A population-based cohort study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP72: The association of anti-tumor necrosis factor and thiopurine therapy with the risk of lymphoma among Inflammatory Bowel Disease patients: A nation-wide study from the epi-IIRN
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP73 Efficacy and safety of escalation to tofacitinib 10 mg BID for patients with UC following loss of response on 5 mg BID maintenance therapy: Results from OCTAVE open-label, long-term extension study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP73: A comparative efficacy and safety analysis of subcutaneous infliximab and vedolizumab in patients with Crohn’s Disease and Ulcerative Colitis
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP73: Antibiotic use differentially affects the risk of antidrug antibody formation during anti-TNFα therapy in Inflammatory Bowel Disease
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP73: Predicting endoscopic improvement in Ulcerative Colitis using the Ulcerative Colitis Severity Index (UCSI)
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP73: Treatment of perianal fistulas in Crohn’s disease, seton vs. anti-TNF vs. surgical closure following anti-TNF (PISA): a randomised controlled trial
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP74 Effectiveness of dose escalation in Crohn’s disease patients with insufficient response to standard-dose subcutaneous ustekinumab maintenance therapy: A multicentre international cohort study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP74: Artificial Intelligence Quantifying Endoscopic Severity of Ulcerative Colitis in Gradation Scale
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP74: Comparative effectiveness of vedolizumab and ustekinumab in Crohn’s Disease patients who failed anti-TNF treatment: Interrogating 1019 patients from the UK IBD BioResource
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP74: Efficacy of ustekinumab in perianal Crohn’s disease: the BioLAP multi-centre observational study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP74: Initial Clearance of infliximab is a predictor for the time of formation of anti-drug antibodies
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP75 Efficacy of tofacitinib dose escalation to 10 mg BID in patients with UC after completing maintenance therapy in remission and losing response: Data from OCTAVE open-label, long-term extension study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM